The review discusses the early trials of multikinase tyrosine kinase inhibitors (TKIs) that were initially used to treat RET-altered thyroid cancer and NSCLC, with limited success. The development ...

The product, an oral RET inhibitor, was approved in 2020 by the FDA to treat adults with metastatic RET fusion-positive non-small-cell lung cancer (NSCLC), shortly after Roche paid $775 million ...

Retevmo is a type of medicine called a kinase inhibitor, and it blocks the action of RET gene fusions. By blocking RET fusions, Retevmo can help stop cancer cells from growing and spreading.

Targeted therapy for thyroid cancer with BRAF and RET inhibitors has progressed to Phase II clinical trials with first results on the therapeutic response pending. Molecular pathways in thyroid ...

Other LP-300 Advancements: Lantern’s RADR platform and in-vitro preclinical experiments have shown that LP-300 has mechanistic synergy with EGFR, ALK, MET, and RET inhibitors. Leading clinicians ...

The US FDA has given accelerated approval for Eli Lilly’s RET inhibitor as a treatment for various RET-altered paediatric cancers, making it the first drug in the class available for children ...